I read with great interest the recent article by Beravs-Bervar et al., “Strengthening health technology assessment (HTA) in the European Union: Insights from Slovenia’s implementation journey.” (Int J Technol Assess Health Care. 2026;42(1):e23. https://doi.org/10.1017/S0266462325103383). The article offers an overview of the institutional challenges Slovenia faces in aligning with the EU HTA Regulation, and to that end, fragmentation, limited methodological capacity, and the absence of a formally designated HTA body can indeed be seen as areas for further development (Reference Beravs-Bervar, Goettsch and Gutierrez-Ibarluzea1).
However, the overall characterization of the Slovenian system as “underdeveloped” risks being overly reductive and insufficiently nuanced. In particular, the manuscript appears to underrecognize a key strength of the Slovenian healthcare system, the well-functioning and highly pragmatic pricing and reimbursement (P&R) framework for medicinal products. This framework has demonstrably enabled rapid and equitable access to innovative therapies, placing Slovenia on a par with some of the most advanced jurisdictions globally (Reference Kluszczynski, Nemeth and Władysiuk2).
As acknowledged in the article, medicinal products in Slovenia are already subject to structured evaluation incorporating clinical effectiveness, cost-effectiveness, budget impact, and ethical considerations (Reference Beravs-Bervar, Goettsch and Gutierrez-Ibarluzea1;Reference Detiček, Janzic, Locatelli and Kos3). What distinguishes the Slovenian model is not the absence of HTA principles, but rather their integration within a streamlined, single-payer decision-making process, avoiding institutional duplication and enabling timely access, which is an especially important feature in a small healthcare system with limited human resources (Reference Kluszczynski, Nemeth and Władysiuk2).
While the authors advocate for the establishment of a centralized HTA body, the implicit assumption that increased institutionalization will necessarily improve outcomes warrants careful consideration. Experience from Central and Eastern Europe suggests that greater procedural complexity does not automatically translate into better access, and may, in some cases, delay patient access to innovation (Reference Kluszczynski, Nemeth and Władysiuk2;Reference Jakab, Dimitrova and Houÿez4). In this context, future reforms should aim not only to align with EU requirements but also to preserve the strengths of the existing system, particularly its efficiency, pragmatism, and outcome-oriented approach.
Funding statement
This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.
Competing interests
The author declares none.
